Granted Patent B2

US 12,478,782 · App. 18/083,057 · Granted Nov 25, 2025

Inventors: Stephen L. Bolea (Watertown, MN); Thomas B. Hoegh (Edina, MN); Brian D. Kuhnley (Maple Grove, MN); Dale G. Suilmann (Elk River, MN); Bruce J. Persson (Shoreview, MN); John P. Beck (Prior Lake, MN); Sidney F. Hauschild (Cottage Grove, MN); Wondimeneh Tesfayesus (St. Paul, MN); Jason J. Skubitz (Arden Hills, MN); Mark R. Bosshard (Shoreview, MN); Daniel A. Parrish (Bloomington, MN); Robert E. Atkinson (White Bear Lake, MN)

Assignee: LivaNova USA, Inc.

A61N1/3601A61N1/0556A61N1/3611A61N1/36139A61N1/3615A61N1/37235A61B5/0826A61B5/086A61B5/4818A61N1/36132

Abstract

Claims (32)

1 . A nerve stimulation system, comprising:

a stimulation delivery lead; and

an implantable neurostimulator connected to the stimulation delivery lead, wherein the neurostimulator is configured to:

deliver nerve stimulation therapy to a subject within a first intensity range during a first therapy period of the therapy, wherein the first intensity range is defined using an awake titration while the subject is awake and has a lower bound and an upper bound, wherein the subject is awake during at least an initial portion of the first therapy period, and wherein the upper bound is a discomfort threshold defined based on an indication, from the subject, of discomfort caused by the stimulation;

transition from the first therapy period to a second therapy period of the nerve stimulation therapy subsequent to the first therapy period, the transitioning comprising a cessation of stimulation; and

deliver the nerve stimulation therapy within a second intensity range during the second therapy period, wherein the second intensity range is defined using a sleep titration while the subject is asleep and includes an upper bound that is greater than the discomfort threshold, wherein the subject is asleep during at least an initial portion of the second therapy period;

wherein the neurostimulator is configured to deliver the nerve stimulation therapy to a nerve of the subject for treating a respiratory condition of the subject.

2 . The nerve stimulation system of claim 1 , wherein the cessation of stimulation is due to subject action.

3 . The nerve stimulation system of claim 2 , wherein the subject action is an initiation of a pre-set number of pauses.

4 . The nerve stimulation system of claim 1 , wherein the neurostimulator is further configured to deliver the nerve stimulation therapy at an increasing level of intensity between the cessation of stimulation and the second therapy period.

5 . The nerve stimulation system of claim 1 , wherein the cessation of stimulation is prompted by a signal received from a sensor.

6 . The nerve stimulation system of claim 1 , wherein at least one of the first intensity range or the second intensity range is a range of an amplitude of a current pulse.

7 . A nerve stimulation system, comprising:

a stimulation delivery lead; and

an implantable neurostimulator connected to the stimulation delivery lead, wherein the neurostimulator is configured to:

deliver nerve stimulation therapy to a subject within a first intensity range during a first therapy period of the nerve stimulation therapy, wherein the first intensity range is defined using an awake titration while the subject is awake and has a lower bound and an upper bound, wherein the subject is awake during at least an initial portion of the first therapy period, and wherein the upper bound is a threshold determined based on feedback from the subject; and

deliver the nerve stimulation therapy within a second intensity range during a second therapy period of the nerve stimulation therapy subsequent to the first therapy period, wherein the second intensity range is defined using a sleep titration while the subject is asleep and includes an upper bound that is higher than the upper bound of the first intensity range, and wherein the subject is asleep during at least an initial portion of the second therapy period,

wherein the neurostimulator is configured to deliver the nerve stimulation therapy to a nerve of the subject for treating a respiratory condition of the subject.

8 . The nerve stimulation system of claim 7 , wherein the threshold is a discomfort threshold and the feedback from the subject indicates discomfort caused by the stimulation.

9 . The nerve stimulation system of claim 7 , wherein the neurostimulator is further configured to transition from the first therapy period to the second therapy period, the transitioning comprising a cessation of stimulation.

10 . The nerve stimulation system of claim 9 , wherein the cessation of stimulation is due to subject action.

11 . The nerve stimulation system of claim 10 , wherein the subject action is an initiation of a pre-set number of pauses.

12 . The nerve stimulation system of claim 9 , wherein the cessation of stimulation is prompted by a signal received from a sensor.

13 . The nerve stimulation system of claim 9 , wherein the neurostimulator is further configured to deliver the nerve stimulation therapy at an increasing level of intensity between the cessation of stimulation and the second therapy period.

14 . A method of delivering a nerve stimulation therapy to a subject via an implanted neurostimulator connected to a stimulation delivery lead, the method comprising:

delivering nerve stimulation therapy to the subject a first intensity range during a first therapy period of the therapy, wherein the first intensity range is defined using an awake titration while the subject is awake and has a lower bound and an upper bound, wherein the subject is awake during at least an initial portion of the first therapy period, and wherein the upper bound is a discomfort threshold defined based on an indication, from the subject, of discomfort cause by the stimulation;

transitioning from the first therapy period to a second therapy period of the nerve stimulation therapy subsequent to the first therapy period, the transitioning comprising a cessation of stimulation; and

delivering the nerve stimulation therapy within a second intensity range during the second therapy period, wherein the second intensity range is defined using a sleep titration while the subject is asleep and includes an upper bound that is greater than the discomfort threshold, wherein the subject is asleep during at least an initial portion of the second therapy period;

wherein the neurostimulator is configured to deliver the nerve stimulation therapy to a nerve of the subject for treating a respiratory condition of the subject.

15 . The method of claim 14 , wherein the cessation of stimulation is due to subject action, the subject action being an initiation of a pre-set number of pauses.

16 . The method of claim 14 , further comprising delivering the nerve stimulation therapy at an increasing level of intensity between the cessation of stimulation and the second therapy period.

17 . The method of claim 14 , wherein the cessation of stimulation is prompted by a signal received from a sensor.

Assignments (3)

Continuity (4)

References Cited (400)